{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:32:56Z","timestamp":1788993176990,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.yebeh.2019.02.034","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T13:17:43Z","timestamp":1553951863000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Comparative neuropsychological effects of carbamazepine and eslicarbazepine acetate"],"prefix":"10.1016","volume":"94","author":[{"given":"Kimford J.","family":"Meador","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Falco-Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scheherazade","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Loring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.02.034_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","volume":"62","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0010","series-title":"Wyllie's treatment of epilepsy: principles & practice","article-title":"Cognitive effects of epilepsy and its treatments","author":"Meador","year":"2019"},{"issue":"10","key":"10.1016\/j.yebeh.2019.02.034_bb0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bialer","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.yebeh.2019.02.034_bb0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2019.02.034_bb0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.yebeh.2019.02.034_bb0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2019.02.034_bb0035","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2019.02.034_bb0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","article-title":"Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers","volume":"18","author":"Milovan","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0050","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1212\/WNL.41.10.1537","article-title":"Comparative cognitive effects of carbamazepine and phenytoin in healthy adults","volume":"41","author":"Meador","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0055","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1212\/WNL.45.8.1494","article-title":"Comparative cognitive effects of phenobarbital, phenytoin, and valporate in healthy adults","volume":"48","author":"Meador","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0060","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1528-1157.1999.tb00858.x","article-title":"Differential cognitive effects of carbamazepine and gabapentin","volume":"40","author":"Meador","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0065","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/WNL.56.9.1177","article-title":"Differential cognitive and behavioral effects of carbamazepine and lamotrigine","volume":"56","author":"Meador","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0070","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/01.WNL.0000165994.46777.BE","article-title":"Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers","volume":"64","author":"Meador","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0075","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/01.wnl.0000281104.55418.60","article-title":"Neuropsychological and neurophysiological effects of carbamazepine and levetiracetam","volume":"69","author":"Meador","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.yebeh.2016.07.007","article-title":"Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine","volume":"62","author":"Meador","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0085","series-title":"Peabody picture vocabulary test","author":"Dunn","year":"1997"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0090","series-title":"Vimpat [package insert]","year":"2015"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0095","series-title":"Tegretol [package insert]","year":"2015"},{"issue":"3","key":"10.1016\/j.yebeh.2019.02.034_bb0100","first-page":"46","article-title":"Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium","volume":"8","author":"Gualtieri","year":"2006","journal-title":"MedGenMed"},{"issue":"3","key":"10.1016\/j.yebeh.2019.02.034_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.yebeh.2012.08.019","article-title":"Acute lorazepam effects on neurocognitive performance","volume":"25","author":"Loring","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2019.02.034_bb0110","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.acn.2006.05.007","article-title":"Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs","volume":"21","author":"Gualtieri","year":"2006","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1993.tb02389.x","article-title":"Effects of carbamazepine and phenytoin on EEG and memory in healthy adults","volume":"34","author":"Meador","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0120","series-title":"Symbol Digit Modalities Test. Manual","author":"Smith","year":"1973"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0125","series-title":"Stroop color and word test. A manual for clinical and experimental uses","author":"Golden","year":"1978"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0130","series-title":"Manual: profile of mood states","author":"Lorr","year":"1971"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0135","author":"Columbia University Medical Center"},{"key":"10.1016\/j.yebeh.2019.02.034_bb0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1528-1167.2010.02746.x","article-title":"Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam","volume":"52","author":"Meador","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.034_bb6005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007124.pub3","article-title":"Immediate-release versus controlled release carbamazepine in the treatment of epilepsy","volume":"12","author":"Powell","year":"2014","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019300629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019300629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:26:58Z","timestamp":1761503218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019300629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"alternative-id":["S1525505019300629"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.034","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative neuropsychological effects of carbamazepine and eslicarbazepine acetate","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}